CDKN2A and pancreatic adenocarcinoma: For example, CDKN2A deletion was significantly more common in PAAD met.PC, with 100% of the samples showing deletions compared to 63% in primary PAAD and 52% in PAAD met.Liv. (Fisher’s exact test with Bonferroni correction, adjusted p = 0.027).